CinnaPoietin (epoetin beta biosimilar) / CinnaGen - LARVOL DELTA

Drug Utilization Evaluation of Erythropoietin at a Referral Teaching Hospital in Iran. (PubMed, Adv Pharmacol Pharm Sci) - "PDpoetin® and Cinnapoietin® were given to 52.6% and 47.4% of the study participants, respectively. The sum indexes of erythropoietin use were in line with standard guidelines in 75.84% of the cases. According to our results, in the setting of erythropoietin use in hospitals, physicians need more attention and education in areas such as selecting the proper dose of medication, correct indication of the drug, temporal arrangement of monitoring laboratory items, and the patient's need for iron supplements."

Journal • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients. (PubMed, Am J Nephrol) - P3; "CinnaPoietin® was proved to be non-inferior to Eprex® in the treatment of anemia in ESRD hemodialysis patients. The trial was registered in Clinicaltrials.gov (NCT03408639)."

Clinical • Journal